SEARCH CONTACT US

ACCESSIBILITY

24/7

Headlines

Johny Srouji weighs leaving Apple, raising stakes for the Israeli executive who built its silicon program

Greece approves $750M rocket deal with Elbit amid negotiations for $3.5B Israeli air-defense systems

Intel VP: “We’re just not going to accept subpar products”

Intel’s decision to keep NEX signals stability for Israel’s 350 networking staff

Buzz

Most popular

Daily

Weekly

1

“Other countries have air-defense systems, but Israel’s are better”: Arrow 3 lands in Germany as Israel pursues new mega deals

2

Nice puts Actimize up for sale at a $1.5-2 billion price tag

3

Zafran raises $60 million and doubles valuation as it chooses independence over takeover offers

4

Israeli drone startup Heven hits $1 billion valuation in $100 million round led by IonQ

5

Cybereason founders' 7AI raises record $130 million Series A in breakneck rise

EpiPen

4 stories about EpiPen

מטה חברת טבע תרופות

Teva Jumps on NYSE on a Bit of Good News

21.08.19|Hezi Sternlicht

An opioid-abuse lawsuit settlement reached by drugmakers Endo and Allergan Tuesday could bode well for Teva’s legal future, as does the release of an FDA-approved generic version of EpiPen JR

תרופה מזרק אפיפן מיילן אלרגיה

Teva, Mylan Drop on Announcement of Epinephrine Injector Rival

09.12.18|Lilach Baumer

Novartis’ U.S. division Sandoz announced a planned release for early 2019. The company will sell its drug, which lacks the EpiPen’s auto-injector, for $250 a pair out of pocket, compared to Mylan and Teva’s $300

תרופה מזרק אפיפן מיילן אלרגיה

Teva’s Generic EpiPen Now Available in the U.S. in Limited Numbers

28.11.18|Lilach Baumer

In August, the Israel-headquartered drugmaker won approval to market the first generic EpiPen auto-injectors in the U.S.

תלמידים כיתה בית ספר לימודים ילדים

Teva’s EpiPen Won’t Hit U.S. Market in Time for School Year, Report Says

26.08.18|Dror Reich

The Israeli drugmaker received approval for a first generic version of Mylan’s auto-injector earlier this month